Eli Lilly’s obesity drug Zepbound is now covered by Medicare for sleep apnea treatment, expanding access to the costly ...

Financing was co-led by Forbion and General Atlantic, with participants such as RA Capital Management, OrbiMed, and Lilly ...

Terence Flynn, Biotech Analyst at Morgan Stanley, discusses Eli Lilly's recent stock boost and its designation as Morgan ...

You won't find many companies that rake in greater sales than Amazon (NASDAQ: AMZN). The e-commerce and cloud services giant generated revenue of roughly $620 billion over the last 12 months. The ...

Both Novo Nordisk and Eli Lilly are studying their weight loss drugs to treat fatty liver disease, chronic kidney disease, ...

Americans elect their leaders on the premise that those individuals will be capable of making the right decisions on difficult, as well as easy, issues. An issue on which members of Congress might ...

Americans elect their leaders on the premise that those individuals will be capable of making the right decisions on difficult, as well as easy, issues. An issue on which members of Congress might ...

A UK biotechnology startup is entering the crowded obesity drug market, armed with $411 million and a promising ...

Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f ...

"Coverage for these weight-loss drugs has significant cost implications for employers, as a previous KFF analysis estimated ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...